The Company depends on contract manufacturers and suppliers to fulfill orders, which is essential to its operations. The COVID-19 pandemic has affected and may continue to affect these manufacturers and suppliers, potentially causing delays or difficulties in sourcing products. Such disruptions could adversely impact the Company's business and financial performance. Factors related to the pandemic, including virus variants, vaccination rates, government measures, and potential future outbreaks, may disrupt the supply chain, delay research activities, hinder negotiations with strategic partners, and affect regulatory processes, potentially postponing clinical trials and product commercialization. The Company has received FDA authorization to market DuraGraft and plans to commercialize it in the United States while maintaining international sales. Additionally, the Company intends to develop MAR-FG-001 fat grafting technology. These strategic initiatives require capital, and there is no assurance that sufficient funding will be available. The Company has experienced impacts from COVID-19 and related supply chain shortages.
Marizyme Inc's Comment on Supply Chain
The Company depends on contract manufacturers and suppliers to fulfill orders, which is essential to its operations. The COVID-19 pandemic has affected and may continue to affect these manufacturers and suppliers, potentially causing delays or difficulties in sourcing products. Such disruptions could adversely impact the Company's business and financial performance. Factors related to the pandemic, including virus variants, vaccination rates, government measures, and potential future outbreaks, may disrupt the supply chain, delay research activities, hinder negotiations with strategic partners, and affect regulatory processes, potentially postponing clinical trials and product commercialization. The Company has received FDA authorization to market DuraGraft and plans to commercialize it in the United States while maintaining international sales. Additionally, the Company intends to develop MAR-FG-001 fat grafting technology. These strategic initiatives require capital, and there is no assurance that sufficient funding will be available. The Company has experienced impacts from COVID-19 and related supply chain shortages.
Sources:
Marizyme Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Marizyme Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
